Third Harmonic Bio Inc. (THRD) - Total Liabilities
Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has total liabilities worth $7.21 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Third Harmonic Bio Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Third Harmonic Bio Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Third Harmonic Bio Inc. Competitors by Total Liabilities
The table below lists competitors of Third Harmonic Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Absolent Group AB
ST:ABSO
|
Sweden | Skr702.63 Million |
|
TTS (TRANSPORT TRADE SERVICES)
RO:TTS
|
Romania | RON326.80 Million |
|
Gajah Tunggal Tbk
JK:GJTL
|
Indonesia | Rp12.21 Trillion |
|
Jasuindo Tiga Perkasa Tbk
JK:JTPE
|
Indonesia | Rp768.02 Billion |
|
Nu Skin Enterprises Inc
NYSE:NUS
|
USA | $624.61 Million |
|
Sailfish Royalty Corp
V:FISH
|
Canada | CA$1.38 Million |
|
Bank Net Indonesia Syariah Tbk PT
JK:BANK
|
Indonesia | Rp11.84 Trillion |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
Germany | €3.09 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Third Harmonic Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see THRD stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 54.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Third Harmonic Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual total liabilities of Third Harmonic Bio Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.46 Million | +9.65% |
| 2023-12-31 | $8.63 Million | -10.21% |
| 2022-12-31 | $9.61 Million | -94.54% |
| 2021-12-31 | $175.87 Million | +556.48% |
| 2020-12-31 | $26.79 Million | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more